{"nct_id":"NCT01973049","title":"UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis","status":"COMPLETED","status_verified_date":"2015-09","start_date":"2013-12","start_date_type":null,"primary_completion_date":"2014-08","primary_completion_date_type":"ACTUAL","completion_date":"2014-11","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["BMY"]}